Summary
In this prospective multicenter trial, treatment strategies for 1573 patients with neutropenia <1000/μl and fever ≥38.5° C after cytotoxic chemotherapy were compared. Patients with unexplained fever were randomized to a three-phase sequential study for different established drug regimens. If an infection could be defined microbiologically or clinically, treatment modifications were determined. In phase I, treatment for all patients consisted of acylaminopenicillin (PEN) plus aminoglycoside (AMG); or third-generation cephalosporin (CEPH) plus AMG; or PEN plus CEPH. In 800 patients with unexplained fever the response rates were: PEN/AMG (n=258): 74.4%, CEPH/AMG (n=252): 73.4%; PEN/CEPH (n=290): 70.0%. Total response rate was 72.5%. In phase II, patients not responding after 3 days received PEN/CEPH/vancomycin (n=70) or PEN/CEPH/AMG (n=74). The respective response rates were 52.9% and 55.4%, total 54.2%. If fever did not resolve, the patients received either PEN/CEPH (n=40) or imipenem/cilastatin (n=59) both in combination with amphotericin-B/5-flucytosin/ rifampin. The response rates were 62.5% and 79.7%, respectively (p=0.07), total 72.7%. No significant differences between the treatment modalities compared were found. Analyzing all three phases together, 91.3% of patients with unexplained fever were cured. The response rate was also analyzed according to patients with gram-positive bacteremia (n=183), response rate =82.5%; gram-negative organisms (n=145) 78.6%; fungemia (n=51) 43.1% (p<0.001); lung infiltrates (n=269) 61.3% (p< 0.001); clinically documented infections (n=198) 84.4%; and clinically and microbiologically documented infections (n=84) 82.1%. If infections were diagnosed after at least 5 febrile days, more lung infiltrates and fungal infections occurredp<0.001). Leukocytes rising above 500/μ during the infection predicted better response rates (p<0.001): in unexplained fever 97.8% vs 86.5% and lower death rates 1.5% vs 8.5%. In documented infections the response rates were then 89.9% vs 62.3% and the death rates 7.0% vs 20.5%. Therapy of neutropenic fever and infections must be adapted according to risk factors and should include early empiric antifungal therapy. The therapeutic and prophylactic use of hematopoietic growth factors to overcome neutropenia should be evaluated.
Similar content being viewed by others
References
Bodey GP, Buckley M, Sathe YS, Freireich EJ (1966) Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64:328–340
EORTC, International Antimicrobial Therapy Cooperative Group (1987) Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. N Engl J Med 317:1692–1698
Klastersky J, Glauser MP, Schimpff SC, Zinner SH, Gaya H, EORTC, International Antimicrobial Therapy Cooperative Group (1986) Prospective randomized comparison of three antibiotic regimens for empirical therapy of suspected bacteremic infection in febrile granulocytopenic patients. Antimicrob Agents Chemothery 29:263–270
Estey EH, Keating MJ, McCredie KB, Bodey GP, Freireich EJ (1982) Causes of initial remission induction failure in acute myelogenous leukemia. Blood 60:309–315
O'Hanley P, Easaw J, Rugo H, Easaw S (1989) Infectious disease management of adult leukemic patients undergoing chemotherapy: 1982 to 1986 experience at Stanford University Hospital. Am J Med 87:605–613
Brown AE (1984) Neutropenia, fever, and infection. Am J Med 76:421–428
Barcos M, Lane W, Gomez GA, Han T, Freeman A, Preisler H, Henderson E (1987) An autopsy study of 1206 acute and chronic leukemias (1958 to 1982). Cancer 60:827–837
Anaissie EJ, Fainstein V, Bodey GP, Rolston K, Elting L, Kantarjian H, Cabanillas F, McCredie KB (1988) Randomized trial of beta-lactam regimens in febrile neutropenic cancer patients. Am J Med 84:581–589
Rolston KV, Berkey P, Bodey GP, Anaissie EJ, Khardori NM, Joshi JH, Keating MJ, Holmes FA, Cabanillas FF, Elting L (1992) A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med 152:283–291
Winston DJ, Barnes RC, Ho WG, Young LS, Champlin RE, Gale RP (1984) Moxalactam plus piperacillin versus moxalactam plus amikacin in febrile granulocytopenic patients. Am J Med 77:442–450
Pizzo PA (1993) Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med 328:1323–1332
Del Favero A, Menichetti F, Bucaneve G, Minotti V, Pauluzzi S (1988) Septicaemia due to gram-positive cocci in cancer patients. J Antimicrob Chemother 21:157–165
EORTC international antimicrobial therapy cooperative group (1990) Gram-positive bacteraemia in granulocytopenic cancer patients. Eur J Cancer 26:569–574
Hughes WT, Armstrong D, Bodey GP, Feld R, Mandell GL, Meyers JD, Pizzo PA, Schimpff SC, Shenep JL, Wade JC, Young LS, Yow MD (1990) Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J Infect Dis 161:381–396
European organization for research and treatment of cancer (EORTC) international antimicrobial therapy cooperative group and the national cancer institute of Canada — clinical trials group (1991) Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic patients. J Infect Dis 163:951–958
Karp JE, Dick JD, Angelopulos C, Charache P, Green L, Burke PJ, Saral R (1986) Empiric use of vancomycin during prolonged treatment-induced granulocytopenia. Randomized, double-blind, placebo-controlled clinical trial in patients with acute leukemia. Am J Med 81:237–242
Rubin M, Hathorn JW, Marshall D, Gress J, Steinberg SM, Pizzo PA (1988) gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med 108:30–35
De Jongh CA, Joshi JH, Thompson BW, Newman KA, Finley RS, Moody MR, Salvatore PC, Tenney JH, Drusano GL, Schimpff SC (1986) A double beta-lactam combination versus an aminoglycoside-containing regimen as empiric antibiotic therapy for febrile granulocytopenic cancer patients. Symposium proceedings: Therapy for immunocompromised patients, Kyoto, Japan, June 1985. Am J Med 80:1–119
Kibbler CC, Prentice HG, Sage RJ, Hoffbrand AV, Brenner MK, Mannan P, Warner P, Bhamra A, Noone P (1989) A comparison of double beta-lactam combinations with netilmicin/ureidopenicillin regimens in the empirical therapy of febrile neutropenic patients. J Antimicrob Chemother 23:759–771
Liang R, Yung R, Chau PY, Lam WK, So SY, Todd D (1988) Imipenem/cilastatin as initial therapy for febrile neutropenic patients. J Antimicrob Chemother 22:765–770
Norrby SR, Vandercam B, Louie T, Runde V, Norberg B, Anniko M, Andrien F, Baudrihaye M, Bow E, Burman LA, et al(1987) Imipenem/cilastatin versus amikacin plus piperacillin in the treatment of infections in neutropenic patients: a prospective, randomized multi-clinic study. Scand J Infect Dis [Suppl] 52:65–78
Novakova I, Donnelly P, de Pauw B (1990) Amikacin plus piperacillin versus ceftazidime as initial therapy in granulocytopenic patients with presumed bacteremia. Scand J Infect Dis 22:705–711
Pizzo PA, Hathorn JW, Hiemenz J, Browne M, Commers J, Cotton D, Gress J, Longo D, Marshall D, McKnight J, Rubin M, Skelton J, Thaler M, Wesley R (1986) A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 315:552–558
Verhagen CS, de Pauw B, De Witte T, Janssen J, Williams K, de Mulder P, Bothof T (1987) Randomized prospective study of ceftazidime versus ceftazidime plus cephalothin in empiric treatment of febrile episodes in severely neutropenic patients. Antimicrob Agents Chemother 31:191–196
Winston DJ, Ho WG, Bruckner DA, Champlin RE (1991) Beta-lactam antibiotic therapy in febrile granulocytopenic patients. A randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone. Ann Intern Med 115:849–859
Arroyo J, Medoff G, Kobayashi GS (1977) Therapy of murine aspergillosis with amphotericin B in combination with rifampin of 5-fluorocytosine. Antimicrob Agents Chemother 11:21–25
Ribner B, Keusch GT, Hanna BA, Perloff M (1976) Combination amphotericin B-rifampin therapy for pulmonary aspergillosis in a leukemic patient. Chest 70:681–683
Graybill JR, Ahrens J (1983) Interaction of rifampin with other antifungal agents in experimental murine candidiasis. Rev Infect Dis 5 [Suppl 3]:S620-S625
Medoff G (1983) Antifungal action of rifampin. Rev Infect Dis 5 [Suppl 3]:S614-S619
Glenn J, Cotton D, Wesley R, Pizzo P (1988) Anorectal infections in patients with malignant diseases. Rev Infect Dis 10:42–52
World Health Organization (1979) WHO Handbook for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48. WHO, Geneva
Maschmeyer G, Link H, Hiddemann W, Meyer P, Helmerking M, Eisenmann E, Schmitt J, Adam D (1994) Pulmonary infiltrations in febrile neutropenic patients. Risk factors and outcome under empirical antimicrobial therapy in a randomized multicenter study. Cancer 73:2296–2304
EORTC (1993) Piperacillin/tazobactam plus amikacin versus ceftazidime plus amikacin as therapy for fever in patients with granulocytopenia: a prospective, randomized, multicenter study. The International Antimicrobial Therapy Cooperative Group of the EORTC. American Society for Microbiology, Proceedings of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, 237 (Abstract)
EORTC (1993) Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Ann Intern Med 119:584–593
de Pauw BE, Donnelly P, Boogaerts MA, Mestdagh N, Machin SJ, Goldstone AH, Kelsey HC (1992) Meropenem or ceftazidime as empiric therapy for neutropenic patients. Am Soc Microb Anaheim 393 (Abstract)
Goodman PJ, Feld R, Higgin de Pauw BE, Deresinski S, Donnelly JP, Lane-Allman E (1993) Prognostic factor predicting early antibiotic modification in severely neutropenic febrile cancer patients. Am Soc Clin Oncol Orlando 1993 464 (Abstract)
Novakova IR, Donnelly JP, de Pauw B (1993) Potential sites of infection that develop in febrile neutropenic patients. Leuk Lymphoma 10:461–467
Donnelly JP, Novakova IR, Raemaekers JM, de Pauw BE (1993) Empiric treatment of localized infections in the febrile neutropenic patient with monotherapy. Leuk Lymphoma 9:3–203
Ramphal R, Bolger M, Oblon DJ, Sherertz RJ, Malone JD, Rand KH, Gilliom M, Shands JW, Kramer BS (1992) Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study. Antimicrob Agents Chemother 36:1062–1067
Novakova I, Donnelly JP, de Pauw B (1991) Ceftazidime as monotherapy or combined with teicoplanin for initial empiric treatment of presumed bacteremia in febrile granulocytopenic patients. Antimicrob Agents Chemother 35:672–678
Van der Auwera P, Aoun M, Meunier F (1991) Randomized study of vancomycin versus teicoplanin for the treatment of gram-positive bacterial infections in immunocompromised hosts. Antimicrob Agents Chemother 35:451–457
Martino R (1991) Teicoplanin vs vancomycin as empiric therapy in febrile neutropenic patients. Am Soc Microb Chicago 1991 294 (Abstract)
Rolston KV, Nguyen H, Amos G, Elting L, Fainstein V, Bodey GP (1994) A randomized double-blind trial of vancomycin versus teicoplanin for the treatment of gram-positive bacteremia in patients with cancer. J Infect Dis 169:350–355
DeGregorio MW, Lee WM, Linker RA, Ries CA (1982) Fungal infections in patients with acute leukemia. Am J Med 73:543–548
Gold JW (1984) Opportunistic fungal infections in patients with neoplastic disease. Am J Med 76:458–463
Holleran WM, Wilbur JR, DeGregorio MW (1985) Empiric amphotericin B therapy in patients with acute leukemia. Rev Infect Dis 7:619–624
Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG (1982) Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 72:101–111
Robertson MJ, Larson RA (1988) Recurrent fungal pneumonias in patients with acute nonlymphocytic leukemia undergoing multiple courses of intensive chemotherapy. Am J Med 84:233–239
Lapierre V, Marie JP, Pico JL, Molina L, Andremont A, Lagrange P, Lebeau B, Michalet M, Hollard D, Zittoun R, Hayat M (1992) Intravenous fluconazole versus intravenous amphotericin B in the managemant of febrile neutropenic patients: a multicentric randomized study. Am Soc Microb Anaheim 214 (Abstract)
Anaissie E, Darcwiche R, Mera J, Gentry L, Abi-Said D, Bodey GP (1993) A prospective randomized multicenter study comparing fluconazole to amphotericin B for nosocomial candidiasis. ICAAC 267 (Abstract)
Shelhamer JH, Toews GB, Masur H, Suffredini AF, Pizzo PA, Walsh TJ, Henderson DK (1992) NIH conference. Respiratory disease in the immunosuppressed patient. Ann Intern Med 117:415–431
Bodey GP, Rolston K, Jones P, Alvarez ME, Fainstein V, Steelhammer L (1986) Imipenem/cilastatin as secondary therapy for infections in cancer patients. J Antimicrob Chemother 18 [Suppl]: 161–166
Jones GR, Konsler G, Dunaway R, Ozer H (1993) Outcome of fever and neutropenia episodes in children and young adults: risk factors for recurrent fever after early discontinuation of antibiotics. Am Soc Clin Oncol Orlando 1993 450 (Abstract)
Link H, Boogaerts MA, Carella AM, Ferrant A, Gadner H, Gorin NC, Harabacz I, Harrousseau F, Hervé P, Holldack J, Kolb HJ, Krieger O, Labar B, Linkesch W, Mandelli F, Maraninchi D, Naparstek E, Nicolay U, Niederwieser D, Reiffers J, Rizzoli V, Siegert W, Vernant JP, De Witte T (1992) A controlled trial of recombinant human granulocyte-macrophage colony-stimulating factor after total body irradiation, high-dose chemotherapy and autologous bone marrow transplantation for acute lymphoblastic leukemia or malignant lymphoma. Blood 80:2188–2195
Neidhart J, Mangalik A, Kohler W, Stidley C, Saiki J, Duncan P, Souza L, Downing M (1989) Granulocyte colony-stimulating factor stimulates recovery of granulocytes in patients receiving dose-intensive chemotherapy without bone marrow transplantation. J Clin Oncol 7:1685–1692
Crawford J, Ozer H, Stoller R, Johnson D, Lyman G, Tabbara I, Kris M, Grous J, Picozzi V, Rausch G, Smith R, Gradishar W, Yahanda A, Vincent M, Stewart M, Glaspy J (1991) Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer. N Engl J Med 325:164–170
Ohno R, Tomonaga M, Kobayashi T, Kanamaru A, Shirakawa S, Masaoka T, Omine M, Oh H, Nomura T, Sakai Y, et al (1990) Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med 323:871–877
Pettengell R, Gurney H, Radford JA, Deakin DP, James R, Wilkinson PM, Kane K, Bentley J, Crowther D (1992) Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood 80:1430–1436
Lyman GH, Lyman CG, Sanderson RA, Balducci L (1993) Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy. J Natl Cancer Inst 85:488–493
Trillet-Lenoir V, Green J, Manegold C, Von Pawel J, Gatzemeier U, Lebeau B, Depierre A, Johnson P, Decoster G, Tomita D, Ewen C (1993) Recombinant granulocyte colonystimulating factor reduces the infectious complications of cytotoxic chemotherapy. Eur J Cancer 29A:319–324
Sugar AM (1990) Empiric treatment of fungal infections in the neutropenic host. Review of the literature and guidelines for use. Arch Intern Med 150:2258–2264
Brajtburg J, Powderly WG (1990) Amphotericin B: delivery systems. Antimicroby Agents Chemother 34:381–384
Büchner T, Roos N (1992) Antifungal treatment strategy in leukemia patients. Ann Hematol 65:153–161
Lopez-Berestein G, Bodey GP, Fainstein V, Keating M, Frankel LS, Zeluff B, Gentry L, Mehta K (1989) Treatment of systemic fungal infections with liposomal amphotericin B. Arch Intern Med 149:2533–2536
Lyman CA, Walsh TJ (1992) Systemically administered antifungal agents. A review of their clinical pharmacology and therapeutic applications. Drugs 44:9–35
Jones PG, Rolston KV, Fainstein V, Elting L, Walters RS, Bodey GP (1986) Aztreonam therapy in neutropenic patients with cancer. Am J Med 81:243–248
Elting LS, Bodey GP, Fainstein V (1986) Polymicrobial septicemia in the cancer patient. Medicine 65:218–225
Whimbey E, Kiehn TE, Brannon P, Blevins A, Armstrong D (1987) Bacteremia and fungemia in patients with neoplastic disease. Am J Med 82:723–730
Malik IA, Abbas Z, Karim M (1992) Randomized comparison of oral of loxacin alone with combination of parenteral antibiotics in neutropenic febrile patients [published erratum appears in Lancet 1992 Jul 11; 340 (8811): 128]. Lancet 339:1092–1096
Pico JL, Marie JP, Chiche D, Guiguet M, Andremont A, Lapierre V, Richet H, Tancrede C, Lagrange P, Hayat M, et al (1993) Should vancomycin be used empirically in febrile patients with prolonged and profound neutropenia? Results of a randomized trial. Eur J Med 2:275–280
Author information
Authors and Affiliations
Consortia
Rights and permissions
About this article
Cite this article
Link, H., Maschmeyer, G., Meyer, P. et al. Interventional antimicrobial therapy in febrile neutropenic patients. Ann Hematol 69, 231–243 (1994). https://doi.org/10.1007/BF01700277
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01700277